Digital Mind-Body Therapy for Neoadjuvant Breast Cancer
ConditionNeoadjuvant Therapy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorFudan University
About this trial
This study is a single-center, randomized controlled, prospective trial investigating the application of Digital Mind-Body Therapy based on digital music and biofeedback (DMBT) during neoadjuvant treatment in patients with locally advanced breast cancer.
Eligibility criteria
Qualifiers
Participants voluntarily agree to take part in this study and provide written informed consent.
Female, aged ≥18 years.
Histologically confirmed invasive breast cancer.
Planned to receive neoadjuvant therapy.
Disqualifiers
Presence of distant metastasis.
History of other malignancies, except for adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or other cancers with disease-free survival >5 years.
Immunodeficiency or human immunodeficiency virus (HIV) infection.
Severe dysfunction of the heart, lungs, liver, or kidneys.
Trial design
Treatments tested in this trial
- DMBT
Treatment groups
66 Participants
are divided into 2 treatment groupsLocations
1Fudan University Shanghai Cancer Center200032, ShanghaiShanghai Municipality, China
Sponsors and collaborators
Fudan University
Lead sponsor
Source ClinicalTrials.gov